cancer
Conditions
Interventions
Test group:Take two bags of Bifidobacterium lactis V9 orally every day
control group:Take a placebo orally, two packs daily
Sponsors
Capital Medical University Affiliated Beijing Shijitan Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Histologically or cytologically confirmed as gastric cancer or esophageal cancer, with stage IV tumor. 2. Age: 18-80 years old; 3. The ECOG physical condition score of the Eastern Oncology Collaboration Group ranged from 0 to 2 points; 4. The expected survival period is more than 4 months; 5. Plan to receive chemotherapy treatment. 6. It can be eaten orally; 7. With my consent and having signed the informed consent form, I am willing and capable of complying with the planned visits, research treatments, laboratory tests and other trial procedures.
Exclusion criteria
Exclusion criteria: 1. Patients with active infections or suffering from mental disorders, cardiovascular and cerebrovascular diseases, severe heart and lung dysfunction, or other patients deemed unsuitable for participation in the study by the researcher; 2. Those who have undergone multiple courses of chemotherapy in the past, extensive radiotherapy, advanced age, bone marrow metastasis, severe infection, adrenal insufficiency, or have severe complications; 3. Pregnant women; 4. Patients who fail to receive treatment on time or fully cooperate. 5. Inability to eat orally, intestinal obstruction, intestinal bleeding, severe short bowel syndrome or high-excretion fistula; 6. Currently participating in other clinical researchers; 7. Patients with severe heart disease, diabetes, hyperlipidemia, electrolyte imbalance, abnormal liver and kidney functions, or other patients deemed unsuitable for participation in the study by the researchers. 8. There is any active autoimmune disease or a history of autoimmune disease with an expected recurrence.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| One-year survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| European Organization for Research and Treatment of Cancer Quality of Life Questionnaire,EORTC QLQ-C30;Patient-Generated Subjective Global Assessment;Karnofsky Score,KPS ;Tumor Marker;Fecel metagenomics;Fecel metabolomics; | — |
Countries
China
Contacts
Public ContactShi Hanping
Capital Medical University Affiliated Beijing Shijitan Hospital
Outcome results
None listed